Exploring For Nsclc Neoadjuvant Adjuvant Or Both
Let's dive into the details surrounding For Nsclc Neoadjuvant Adjuvant Or Both.
- Corey J. Langer, MD, FACP; Karen Kelly, MD; Benjamin P. Levy, MD; and Mark A. Socinski, MD, review emerging data and ...
- Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, touches on unanswered questions regarding ...
- In this session Dr David Carbone highlights a new treatment paradigm
- Heather A. Wakelee, MD, Stanford University, Stanford, CA discuss the efficacy of
- Paul Van Schil, MD, PhD, University Hospital Antwerp (UZA), Edegem, Belgium, discusses the evolution of surgery
In-Depth Information on For Nsclc Neoadjuvant Adjuvant Or Both
H. Jack West, MD, and Julia Rotow, MD, discuss data on perioperative approaches presented at ASCO 2023. In this segment, Benjamin P. Levy, MD, discusses the role of Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, provides a comparison of Justin Gainor, MD, director of targeted immunotherapy and assistant professor of medicine at Harvard Medical School, discusses ...
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses biomarkers that can predict if a patient will require
That wraps up our extensive overview of For Nsclc Neoadjuvant Adjuvant Or Both.
